Healthcare & Medical, Science
2023 ESC guidelines, What does it mean to you and your practice in the UK?
AstraZeneca
A webinar, led by experts in the field of cardiology across disciplines. Following the publication of the 2023 ESC guidelines (‘Focused update on heart failure’), this webinar allows healthcare professionals to hear from their peers about what the guideline change is and the reasons behind it. As well as outlining the SGLT2i data that has resulted in the update, it details key information regarding clinical implementation, to support healthcare professionals in daily practice to improve patient outcomes.
Webinar
Healthcare & Medical, Science
A holistic approach to the management of hyperkalaemia, Heart failure specialist nurse and the multidisciplinary team
AstraZeneca
This presentation has been developed for heart failure specialist nurses (HFSNs) in the UK, providing an overview of hyperkalaemia in patients with heart failure and the role of HFSNs in managing hyperkalaemia in secondary care. This presentation aims to provide HFSNs information about the impact of hyperkalaemia in patients with heart failure, and how to identify and manage these patients in secondary care. The presentation will also highlight the importance of HFSNs, including their role in optimising outcomes for patients with heart failure and hyperkalaemia and as part of a multidisciplinary team in the heart failure care network.
Seminar
Healthcare & Medical, Science
Achieving guideline-directed medical therapy and optimising outcomes in CKD patients with hyperkalaemia
AstraZeneca
This presentation has been developed for nephrologists in the UK: providing an overview of hyperkalaemia in patients with CKD. The presentation aims to provide nephrologists with information about the impact of hyperkalaemia in their CKD patients and how to identify and manage these patients in secondary care. The presentation will also highlight the importance of nephrologists including their role in optimising outcomes for patients with CKD and hyperkalaemia as part of a multidisciplinary team.
Webinar
Healthcare & Medical, Science
Achieving guideline-directed medical therapy and optimising outcomes in HF patients with hyperkalaemia
AstraZeneca
A webinar developed for cardiologists in the UK providing an overview of hyperkalaemia in patients with heart failure and clinical guidance on delivering guideline-directed medical therapy in secondary care. This webinar aims to provide cardiologists information about clinical guidance and practical advice on managing patients with heart failure and hyperkalaemia: and the importance of their role in collaborating within a multidisciplinary team.
Webinar
Healthcare & Medical, Science
Are you considering cardiovascular risk in type 2 diabetes?
AstraZeneca
The treatment of type 2 diabetes (T2D) has evolved from blood glucose control being recognised as the main focus of management. The latest update to the NICE guidelines (NG28) has seen a paradigm shift in how T2D is managed, with the updated guideline recognising cardiovascular risk management as equally important as blood glucose control. This 8-minute video will take you through, How the treatment of T2D has changed since the last NICE guidelines came out in 2015 The impact the recommended updates in the latest NICE guidelines will have in the first-line treatment of T2D.
Training Video
Healthcare & Medical, Science
Breaking the Cycle, Managing Hyperkalaemia for Long-Term Cardiorenal Protection
AstraZeneca
A virtual webinar, led by experts in the cardiorenal field. As well as outlining the guidelines around use of K+ binders to manage hyperkalaemia, our specialist speakers provide insights into the importance of achieving long-term cardiorenal protection for patients living with CKD and HF. Patient case studies that provide key information regarding clinical implementation are used to support healthcare professionals in daily practice to improve patient outcomes.
Webinar
Healthcare & Medical, Science
Cardiorenal disease in type 2 diabetes, a paradigm shift in management
AstraZeneca
A thorough presentation developed for UK-based endocrinologists, diabetologists and diabetes-specialist nurses, highlighting the paradigm shift to cardiorenal management in type 2 diabetes mellitus (T2DM). This presentation focuses on clinical outcomes T2DM, heart failure with reduced and preserved ejection fraction, and chronic kidney disease for NICE recommended therapies and key information key information regarding implementation to support healthcare professionals in daily practice to improve patient outcomes.
Seminar
Healthcare & Medical, Science
Cardiorenal protection, a risk-based approach to managing type 2 diabetes in addition to glycaemic control
AstraZeneca
An interactive and engaging presentation developed for UK based GPs, practice based and primary care network pharmacists and nurses, sharing the recent NICE updates to the NG28 guidelines for Type 2 diabetes management, This presentation provides a comprehensive background to the value of a risk-based approach both clinically and for patient-outcomes, and includes meta-data analysis results, As well as outlining the data supporting the revised approach, it details guidance on how to implement the new treatment strategy in daily practice to improve patient outcomes,
Literature
Healthcare & Medical, Science
Cardiorenal risk-based management in T2DM, the latest standard of care
AstraZeneca
This slide deck covers the impact of T2DM on the cardiorenal system and cardiorenal protection offered with specific treatment. It also discusses the opportunities available in primary care using a risk-based approach in the management of T2DM and how to initiate current treatment options in patients.
Seminar
Healthcare & Medical, Science
Implementing the NICE type 2 diabetes guidelines
AstraZeneca
The latest update to the NICE guideline (NG28) has seen a paradigm shift in the treatment of type 2 diabetes (T2D) and how it is managed, with the updated guideline recognising cardiovascular risk management as equally important as blood glucose control. It is important to now consider how to implement the updated NICE guideline in clinical practice. This ~7-minute video will provide, Practical guidance on how to implement the new guidelines with your T2D patients in Primary care Tips and advice on how to engage with your T2D patient when discussing the importance of cardiovascular risk management with them.
Training Video
Healthcare & Medical, Science
Improving access to cardiorenal protection in T2DM, implementing NICE guidance
AstraZeneca
Developed for primary care HCPs, this presentation supports HCPs in understanding the change in recent type 2 diabetes mellitus (T2DM) guidelines, how this incorporates cardiovascular and renal management, and how to select the most appropriate treatment for their patients. With practical advice and guidance from guideline bodies as well as expert speakers, this presentation supports HCPs to better manage people in their care with T2DM.
Seminar
Healthcare & Medical, Science
Management of adverse events and monitoring patients on LYNPARZA
AstraZeneca
The presentation aims to examine the safety profile of LYNPARZA in combination with abiraterone + prednisone/prednisolone, review the management of common AEs reported with use of LYNPARZA and raise awareness of serious but rare adverse events.
Seminar
Healthcare & Medical, Science
Managing Patients with T2D
AstraZeneca
Developed for UK healthcare professionals (HCPs), this presentation has been developed to support HCPs in understanding the complications of type 2 diabetes (T2D) and management, including guideline-recommended pharmacological treatments and lifestyle changes. With practical advice and guidance on patient management, this presentation ensures HCPs feel confident in managing T2D and its complications with a risk-based approach in their everyday practice.
Training Course
Healthcare & Medical, Science
NICE type 2 diabetes guideline – what’s changed?
AstraZeneca
The latest update to the NICE guideline (NG28) has seen a paradigm shift in the treatment of type 2 diabetes (T2D) and how it is managed, with the updated guideline recognising cardiovascular risk management as equally important as blood glucose control. This ~7-minute video will look in more detail at, The key treatment recommendations in the updated guideline. How to translate the update guideline into the daily management of your T2D patients within Primary Care.
Training Video
Healthcare & Medical, Science
Optimising T2D management using NICE guideline 28 (NG28)
AstraZeneca
Developed for UK healthcare professionals (HCPs), this presentation has been developed to support HCPs in the understanding the guideline paradigm shift in a risk-based approach to the management of type 2 diabetes (T2D) based on guidance from the NICE Guideline 28 (NG28) and analysing how this can be implemented in clinical practice. With practical advice and guidance on patient assessment and management, this presentation aims to help HCPs improve their confidence in assessing and treating patients with T2D, and know how to minimise risk of cardiovascular outcomes.
Training Course
Healthcare & Medical, Science
Protecting cardiorenal function in patients with T2DM
AstraZeneca
This highly practical presentation provides information for HCPs in primary care practice about how to manage those in their care with type 2 diabetes mellitus (T2DM) and risk of cardiorenal dysfunction. Providing tools, acronyms, advice and data, this presentation includes a deep dive into available treatments for T2DM. It also equips HCPs to best support those in their care, with guidance on productive consultations, to ensure people with T2DM are being treated for cardiorenal risk in their management.
Seminar
Healthcare & Medical, Science
Simplifying the management of heart failure across the range of ejection fraction
AstraZeneca
A thorough presentation developed for UK based cardiologists and cardiology-specialist nurses, highlighting the evolving landscape in heart failure, and the burden of HFrEF (heart failure with reduced ejection fraction) and HFpEF (heart failure with preserved ejection fraction) on those suffering from these.
Seminar
Healthcare & Medical, Science
Take up the challenge for your eligible patients – who are the patients?
AstraZeneca
The presentation aims to highlight eligible patients for LYNPARZA (olaparib) combination therapy in mCRPC. The presentation will discuss a hypothetical eligible patient for LYNPARZA and will explore how his treatment can be managed to achieve prolonged median rPFS, as well as management of adverse events and dosing.
Seminar
Healthcare & Medical, Science
Tick tock, slow the eGFR clock, managing kidney risk in people with T2D
AstraZeneca
A thorough presentation developed for UK based healthcare professionals, detailing the impact of declining eGFR on patients and mortality risk, and the impact of early intervention. This deck also contextualises the outcomes of landmark clinical trials, and highlights the impact of dapagliflozin treatment on a hypothetical patient profile.
Seminar
Healthcare & Medical, Science
Turning numbers into action, optimising care in T2DM and CKD
AstraZeneca
Developed to support HCPs in primary care to better understand and apply the learnings from clinical trials reporting into their day-to-day practice. Spanning trial design, inclusion criteria, endpoints, reporting of absolute risk reduction, relative risk reduction, Numbers Need to Treat, and much more, this presentation contextualises clinical trial information through the lens of a key trial in chronic kidney disease relevant to primary care physicians’ practice.
Seminar
Healthcare & Medical, Science
Understanding the benefits of holistic care in T2D
AstraZeneca
A thorough presentation developed for UK-based diabetes specialist nurses, to help HCPs look beyond sugar management, through understanding the holistic cardiovascular, renal and metabolic impact of their patients' type 2 diabetes, and provide clear information on what they should be looking out for beyond HbA1c. This presentation focuses on the burden of cardiorenal disease and type 2 diabetes, the importance of early treatment, and the use of SGLT2 inhibitors as first-line treatment for patients with type 2 diabetes, heart failure, and chronic kidney disease as recommended by NICE in the NG28 guideline.
Seminar
Healthcare & Medical, Science
Understanding the Benefits of Holistic Care in T2DM
AstraZeneca
A thorough presentation developed for UK-based diabetes specialist nurses, to help HCPs look beyond sugar management, through understanding the holistic cardiovascular, renal and metabolic impact of their patients’ type 2 diabetes and provide clear information on what they should be looking out for beyond HbA1c. This presentation focuses on the burden of cardiorenal disease and type 2 diabetes, the importance of early treatment, and the use of SGLT2 inhibitors as first-line treatment for patients with type 2 diabetes, heart failure, and chronic kidney disease as recommended by NICE in the NG28 guideline.
Training Course
Healthcare & Medical, Science
Understanding the impact of T2D
AstraZeneca
Developed for UK Healthcare Professionals (HCPs). This presentation has been developed to support HCPs in understanding the prevalence and impact of type 2 diabetes (T2D) on the healthcare system and patients, and to gain insights into the links between T2D, chronic kidney disease (CKD) and heart failure (HF). This presentation ensures HCPs have an in-depth understanding of the impact of T2D to help better manage patients in their care.
Event
